ArticleBMC ophthalmology2026
Improvement of uncorrected visual acuity and contrast sensitivity using Aurovue Vivid Continuous Focus Vision (CFV) lens in cataract patients at RSCM Kirana.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe primary goal of cataract surgery has evolved beyond visual restoration toward comprehensive refractive outcomes. In aging yet functionally active populations such as Indonesia, access to premium multifocal intraocular lenses (IOLs) remains limited, creating demand for cost-effective extended-depth-of-focus (EDOF) alternatives.
objectiveTo evaluate visual performance, contrast sensitivity, defocus profile, IOL stability, and patient-reported outcomes following implantation of the Aurovue Vivid Continuous Focus Vision (CFV) IOL.
methodsThis prospective interventional case series included 25 eyes of 19 patients undergoing phacoemulsification with Aurovue Vivid CFV implantation. Assessments included uncorrected distance (UCDVA), intermediate (UCIVA), and near (UCNVA) visual acuity, corrected distance visual acuity (CDVA) at one month, binocular defocus curve, photopic contrast sensitivity, ultrasound biomicroscopy for tilt/decentration, and patient satisfaction.
resultsAll eyes completed follow-up. Statistically significant improvements were observed: UCDVA from 1.06 ± 0.49 to 0.18 ± 0.16 logMAR (p < 0.001), UCIVA from 0.97 ± 0.41 to 0.35 ± 0.23 logMAR (p < 0.001), UCNVA from 1.05 ± 0.49 to 0.55 ± 0.16 logMAR (p < 0.001), postoperative CDVA of 0.00 (range 0.0-0.4) logMAR with 76% of eyes achieving 0 logMAR and photopic contrast sensitivity from 1.05 (range 0-1.65) to 1.65 (range 1.35-1.85) log units (p < 0.001). The binocular defocus curve demonstrated a peak acuity of 0.06 logMAR at 0 D defocus (distinct from the routine postoperative UCDVA of 0.18 logMAR), with maintained acuity (≤ 0.20 logMAR) up to approximately - 2.0 D. IOL stability was excellent: mean tilt angles 90.30°-90.50° and median decentration 0.06 mm. Patient satisfaction reached 100% with 76% spectacle independence; mild non-functional glare was reported by 20%.
conclusionIn this short-term exploratory case series, the Aurovue Vivid CFV achieved satisfactory visual outcomes across all distances, with preserved contrast sensitivity, stable IOL positioning, and high patient-reported comfort. These preliminary data suggest the lens may represent a viable, cost-effective option to bridge the gap between monofocal and premium multifocal solutions; longer-term, comparative studies are warranted to confirm durability and relative performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.